Your browser doesn't support javascript.
loading
Update on Immunotherapy Cardiotoxicity: Checkpoint Inhibitors, CAR T, and Beyond.
Patel, Murti; Hudson, Olivia; Han, Jingnan; Kondapalli, Lavanya; Arora, Garima; Hawi, Riem; Andrikopoulou, Efstathia; Estes, Courtney; Johnson, Abigail M; Lenneman, Carrie.
Afiliação
  • Patel M; University of Alabama at Birmingham (UAB) Heersink School of Medicine, Birmingham, AL, USA.
  • Hudson O; University of Alabama at Birmingham (UAB) Heersink School of Medicine, Birmingham, AL, USA.
  • Han J; University of Alabama at Birmingham (UAB) Heersink School of Medicine, Birmingham, AL, USA.
  • Kondapalli L; University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, USA.
  • Arora G; University of Alabama at Birmingham (UAB) Heersink School of Medicine, Birmingham, AL, USA.
  • Hawi R; University of Alabama at Birmingham (UAB) Heersink School of Medicine, Birmingham, AL, USA.
  • Andrikopoulou E; University of Alabama at Birmingham (UAB) Heersink School of Medicine, Birmingham, AL, USA.
  • Estes C; University of Alabama at Birmingham (UAB) Heersink School of Medicine, Birmingham, AL, USA.
  • Johnson AM; University of Alabama at Birmingham (UAB) Heersink School of Medicine, Birmingham, AL, USA.
  • Lenneman C; University of Alabama at Birmingham (UAB) Heersink School of Medicine, Birmingham, AL, USA. clenneman@uabmc.edu.
Curr Treat Options Oncol ; 24(11): 1489-1503, 2023 Nov.
Article em En | MEDLINE | ID: mdl-37624557
ABSTRACT
OPINION STATEMENT Immunotherapy is an innovative approach to cancer treatment that involves using the body's immune system to fight cancer. The landscape of immunotherapy is constantly evolving, as new therapies are developed and refined. Some of the most promising approaches in immunotherapy include immune checkpoint inhibitors (ICIs) these drugs target proteins on the surface of T-cells that inhibit their ability to attack cancer cells. By blocking these proteins, checkpoint inhibitors allow T-cells to recognize and destroy cancer cells more effectively. CAR T-cell therapy this therapy involves genetically modifying a patient's own T-cells to recognize and attack cancer cells. CAR T-cell therapy exhibits favorable response in many patients with refractory hematological cancers with growing clinical trials in solid tumors. Immune system modulators these drugs enhance the immune system's ability to fight cancer by stimulating the production of immune cells or inhibiting the activity of immune-suppressing cells. While immunotherapy has shown great promise in the treatment of cancer, it can also pose significant cardiac side effects. Some immunotherapy drugs like ICIs can cause myocarditis, which can lead to chest pain, shortness of breath, and heart failure. Other cardiac side effects of ICIs include arrhythmias, pericarditis, vasculitis, and accelerated atherosclerosis. It is important for patients receiving immunotherapy to be monitored closely for these side effects, as prompt treatment can help prevent serious complications. Patients should also report any symptoms to their healthcare providers right away, so that appropriate action can be taken. CAR T-cell therapy can also illicit an exaggerated immune response creating cytokine release syndrome (CRS) that may precipitate cardiovascular events arrhythmias, myocardial infarction, and heart failure. Overall, while immune modulating therapy is a promising and expanding approach to cancer treatment, it is important to weigh the potential benefits against the risks and side effects, especially in patients with high risk for cardiovascular complications.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Receptores de Antígenos Quiméricos / Cardiopatias / Insuficiência Cardíaca / Neoplasias Limite: Humans Idioma: En Revista: Curr Treat Options Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Receptores de Antígenos Quiméricos / Cardiopatias / Insuficiência Cardíaca / Neoplasias Limite: Humans Idioma: En Revista: Curr Treat Options Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos